🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

new lab preprint - using proteomics and protein co-variation to infer protein association networks across 11 human tissues to study what determines tissue differences and to prioritize disease genes in GWAS linked genes through tissue specific networks biorxiv.org/content/10.110…

Great Open Targets collaboration with many others. It was started by Danish Memon while at EMBL-EBI. The MS work was by Marc van Oostrum Andrea Fossati Fabian Frommelt and others at IMSB_ETH. Additional work by IntAct at EBI team members.

📢 On World #IBD Day weekend Carl Anderson and I are delighted to introduce Open-IBD! £11M funding from Open Targets and Wellcome Sanger Institute Open-IBD will study serial multi-omics and longterm outcomes from diagnosis in 1,000 people with IBD More👇 opentargets.org/news/open-ibd-…

Launching ahead of #WorldIBDDay, Open-IBD is an ambitious project that aims to uncover new ways to predict, monitor, and treat #Crohnsdisease and #ulcerativecolitis 🔎 Read more about it here 👇 sanger.ac.uk/news_item/ambi…

Designing projects we look for opportunities to make a difference in our understanding of disease and where we can work with exceptional scientists. Looking forward to what we can accomplish here for IBD with an amazing team.

Our gene pages now link out to Open Targets Platform associations pages — view diseases associated with your gene and explore relevant genetic, pathway, drug, bibliography evidence and more. pic.x.com/UU4oKzVsxu

Some great discussion so far at our workshop on effector gene reporting standards, looking forward to more today! Common Metabolic Diseases Knowledge Portal Open Targets

Genome-wide association studies focusing on SNPs have advanced our understanding of certain diseases but are reaching limits for some conditions. This Nature Reviews Genetics review highlights how exploring copy number variation can help break these limits. nature.com/articles/s4157…

Advances in LLMs & other computational tools could help patients + clinicians shorten the #RareDisease diagnostic journey – even when doctors haven’t seen the condition before. Experts are sharing #AI insights & more at the Science in Society 2024 meeting

New research published today suggests genetic testing could lower the risk of adverse drug reactions for thousands of patients with cancer. Find out more via this link: ow.ly/Uuz750TXQ3r

Pleased to announce our Large Scale #PGx analysis in cancer patients within 100,000 Genomes Project combining WGS + medical records to show potential impact of genetic testing on reducing adverse drug reactions: ascopubs.org/doi/10.1200/JC…

I am very excited to share our paper on Pharmacogenomics analysis of patients with cancer within the 100,000 Genomes Project. Fantastic  collaboration with Ellie McDonagh, Ivone Leong, and Valentina Cipriani, William Harvey Research Institute, Genomics England, ascopubs.org/doi/10.1200/JC…

Opportunity Alert! The Data Coordination and Dissemination (DCD) Workstream, led by Drs Alan Rubin (WEHI) and Julia Foreman (DECIPHER, EMBL-EBI), is looking to add new members to the group! 🧵1/2

Interested in facilitating the sharing and discoverability of MAVE projects and MAVE data? Join the Atlas of Atlas of Variant Effects Alliance Alliance Data Coordination and Dissemination workstream: varianteffect.org/leadership-opp…

Got a PhD in bioinformatics or quantiative/CS degree? Want to work with AI on real world health care data, using some of the biggest datasets in the world? Want to live in Cambridge UK and work in European EMBL? This job in my research group is for you! embl.org/jobs/position/…

This is a very exciting opportunity to join a project across Ewan Birney and Open Targets teams at EMBL-EBI - apply now!

OUT NOW in Nucleic Acids Res! A look back at all the changes to the Open Targets Platform in the past two years 🖥️🧬 We've focused on adding data and analyses to help build therapeutic hypotheses, and refining the web interface to give you more control over what you see Take a look!

Coming soon to a screen near you... 👀 In our spring 2025 release, Open Targets Genetics will merge with the Open Targets Platform, and we're excited to share a sneak preview with you Take a look!

Check out this exciting sneak preview from our Open Targets team of our new merged Platform with integration of large scale post-GWAS statistical analysis and ability to search for genetic variants across rare and common disease/trait associations!

There has been a huge amount of achievements over the past 2 years reflected in the Open Targets Platform to help build therapeutic hypotheses - congratulations team! Check out our summary video and NAR paper for more details